NeuroBo Pharmaceuticals Receives FDA Clearance for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH

May 2, 2023

(24/7 MARKET NEWS) – NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) stated, this morning, that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist and NeuroBo plans to initiate a two-part, Phase 2a clinical trial of DA-1241, for the treatment of nonalcoholic steatohepatitis (NASH), in the third quarter of 2023.

NeuroBo Pharmaceuticals is trading at $0.69, up $0.005 (+0.73%), on 902K premarket shares traded.

Its 52-week range is $0.551 to $63.85. It’s been bouncing between 55-cents and near a dollar for all of 2023; its premarket high is 90-cents and breaking through that channel to the upside would be very bullish.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to 247marketnews.com or https://247marketnews.com/terms-disclaimer/ for further information.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.